HN30 Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Restart Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.067 |
| 52 Week High | CA$0.094 |
| 52 Week Low | CA$0.0002 |
| Beta | 0.82 |
| 1 Month Change | 192.98% |
| 3 Month Change | 1,236.00% |
| 1 Year Change | 1,236.00% |
| 3 Year Change | -76.14% |
| 5 Year Change | -92.23% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| HN30 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 122.7% | -0.9% | 0.3% |
| 1Y | 1,236.0% | -6.0% | 12.9% |
Return vs Industry: HN30 exceeded the German Biotechs industry which returned -3.9% over the past year.
Return vs Market: HN30 exceeded the German Market which returned 13.3% over the past year.
Price Volatility
| HN30 volatility | |
|---|---|
| HN30 Average Weekly Movement | 5,079.1% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HN30's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HN30's weekly volatility has increased from 2450% to 5079% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Steve Loutskou | www.restartlife.co |
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024.
Restart Life Sciences Corp. Fundamentals Summary
| HN30 fundamental statistics | |
|---|---|
| Market cap | €1.21m |
| Earnings (TTM) | €10.12k |
| Revenue (TTM) | n/a |
119.7x
P/E Ratio-63.5x
P/S RatioIs HN30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HN30 income statement (TTM) | |
|---|---|
| Revenue | -CA$28.35k |
| Cost of Revenue | CA$0 |
| Gross Profit | -CA$28.35k |
| Other Expenses | -CA$43.39k |
| Earnings | CA$15.05k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00084 |
| Gross Margin | 100.00% |
| Net Profit Margin | -53.09% |
| Debt/Equity Ratio | -10.2% |
How did HN30 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 00:41 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Restart Life Sciences Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.